John Kozarich Net Worth

The estimated Net Worth of John W Kozarich is at least $9.81 Milión dollars as of 24 April 2024. John Kozarich owns over 2,893 units of Ligand Pharmaceuticals stock worth over $4,383,696 and over the last 21 years he sold LGND stock worth over $5,058,615. In addition, he makes $369,900 as Non-Executive Independent Chairman of the Board at Ligand Pharmaceuticals.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

John Kozarich LGND stock SEC Form 4 insiders trading

John has made over 31 trades of the Ligand Pharmaceuticals stock since 2012, according to the Form 4 filled with the SEC. Most recently he exercised 2,893 units of LGND stock worth $113,840 on 24 April 2024.

The largest trade he's ever made was buying 100,000 units of Ligand Pharmaceuticals stock on 23 August 2019 worth over $46,000. On average, John trades about 2,357 units every 56 days since 2004. As of 24 April 2024 he still owns at least 42,523 units of Ligand Pharmaceuticals stock.

You can see the complete history of John Kozarich stock trades at the bottom of the page.

John Kozarich biography

Dr. John W. Kozarich Ph.D. serves as Non-Executive Independent Chairman of the Board of the Company. Dr. Kozarich has served as interim Chief Executive Officer of Curza Global, LLC, a biopharmaceutical company, where he has served as a member of the board of directors since February 2019. Dr. Kozarich also serves as Distinguished Scientist Emeritus of ActivX Biosciences, Inc., and previously served as ActivX’s Chairman and President from 2004 through March 2017. From 1992 to 2001, Dr. Kozarich was vice president at Merck Research Laboratories and previously held professorships at the University of Maryland and Yale University School of Medicine. Dr. Kozarich is also an adjunct professor of Chemical Physiology at the Scripps Research Institute and serves on the board of Intec Pharma Ltd., a publicly-traded biotechnology company. Previously, Dr. Kozarich served as a director of ActiveX Biosciences Inc., Corium Intl, Novelion Therapeutics and Retrophin, Inc. He is also a recipient of the Distinguished Scientist Award from the San Diego Section of the American Chemical Society. Dr. Kozarich earned his B.S. in chemistry, summa cum laude, from Boston College, his Ph.D. in biological chemistry from the Massachusetts Institute of Technology, and was an NIH Postdoctoral Fellow at Harvard. In selecting Dr. Kozarich to serve as a director, the board considered, among other things, his valuable pharmaceutical and international experience, including his service at Merck Research Laboratories, which is part of one of the world’s largest pharmaceutical companies, and his service with ActivX Biosciences, Inc., Novelion Therapeutics Inc. and Corium Intl. Our company also benefits from Dr. Kozarich’s financial and accounting experience in the pharmaceutical and biotechnology industries.

What is the salary of John Kozarich?

As the Non-Executive Independent Chairman of the Board of Ligand Pharmaceuticals, the total compensation of John Kozarich at Ligand Pharmaceuticals is $369,900. There are 10 executives at Ligand Pharmaceuticals getting paid more, with John Higgins having the highest compensation of $6,770,380.

How old is John Kozarich?

John Kozarich is 70, he's been the Non-Executive Independent Chairman of the Board of Ligand Pharmaceuticals since 2017. There are no older and 16 younger executives at Ligand Pharmaceuticals.

What's John Kozarich's mailing address?

John's mailing address filed with the SEC is 555 HERITAGE DRIVE, SUITE 200, JUPITER, FL, 33458.

Insiders trading at Ligand Pharmaceuticals

Over the last 21 years, insiders at Ligand Pharmaceuticals have traded over $205,340,014 worth of Ligand Pharmaceuticals stock and bought 2,116,600 units worth $27,601,439 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Partners L P/Ilbiotechnolog... a Partners L P/Ilbiotechnolog.... On average, Ligand Pharmaceuticals executives and independent directors trade stock every 22 days with the average trade being worth of $2,239,733. The most recent stock trade was executed by Octavio Espinoza on 28 August 2024, trading 753 units of LGND stock currently worth $50,090.

What does Ligand Pharmaceuticals do?

ligand, a pharmaceutical company, is assembling a large and diverse portfolio of current and near-term commercial revenue generating assets to assist the long-term financial growth of the company. we operate this business on a lean cost structure that allows us to maximize cash flow and ultimately deliver a meaningful return for our shareholders.

Complete history of John Kozarich stock trades at Intec Parent Inc, Ligand Pharmaceuticals a Retrophin

Ligand Pharmaceuticals executives and stock owners

Ligand Pharmaceuticals executives and other stock owners filed with the SEC include:

• John Higgins,
  Chief Executive Officer, Director
• Matthew Foehr,
  President, Chief Operating Officer
• Matthew Korenberg,
  Chief Financial Officer, Executive Vice President - Finance
• Charles Berkman,
  Senior Vice President, General Counsel, Secretary
• John L. Higgins,
  CEO & Exec. Director
• Matthew W. Foehr,
  Pres & COO
• Matthew E. Korenberg,
  Exec. VP of Fin. & CFO
• Charles S. Berkman J.D.,
  Sr. VP, Gen. Counsel & Sec.
• Charles S. Berkman,
  Sr. VP, Gen. Counsel & Sec.
• Sarah Boyce,
  Independent Director
• John Kozarich,
  Non-Executive Independent Chairman of the Board
• Stephen Sabba,
  Independent Director
• Jason Aryeh,
  Independent Director
• Todd Davis,
  Independent Director
• Sunil Patel,
  Independent Director
• Nancy Gray,
  Independent Director
• John Lamattina,
  Independent Director
• Simon Latimer,
  Head of Investor Relations
• Patrick Lucy,
  Sr. VP & CBO Protein Expression Bus.
• Dr. Vincent D. Antle,
  Sr. VP of Technical Operations & QA - Capitsol
• Dr. Keith Marschke,
  Sr. VP of Biology & Scientific Affairs
• Audrey Warfield-Graham,
  Sr. VP of HR
• Todd Pettingill,
  Director of Corp. Devel.
• Patrick O'Brien,
  Sr. VP of Investor Relations
• Jason Haas,
  Director
• Corp Plc Elan,
  10% owner
• Andres Negro Vilar,
  Exe V-P, R & D, CSO
• Partners L P/Ilbiotechnolog...,
  
• Bruce Peacock,
  Director
• Zofia E Dziewanowska,
  VP, Clinical Research
• Partners L P/Ilbiotechnolog...,
  
• Melanie J Herman,
  Director of Accounting
• Nishan M De Silva,
  VP, Corporate Development
• David M Knott,
  10% owner
• Syed Kazmi,
  VP, Bus. Dev. & Strategic Plan
• Martin Meglasson,
  V-P, Discovery Research
• Pharmaceuticals Inc Ligand,
  Director
• Partners L P/Ilbiotechnolog...,
  
• Partners L P/Ilbiotechnolog...,
  
• Partners L P/Ilbiotechnolog...,
  
• Steven J Burakoff,
  Director
• Brigette Roberts,
  Director
• Partners L P/Ilbiotechnolog...,
  
• John P Sharp,
  VP Finance and CFO
• Daniel S Loeb,
  Director
• Michael A Rocca,
  Director
• John Groom,
  Director
• Taylor Crouch,
  Sr. V-P, Ops & Pres. Int'l
• Partners L P/Ilbiotechnolog...,
  
• Jeffrey R Perry,
  Director
• Alexander D Cross,
  Director
• William A Petttit,
  Sr. V-P, HR and Administration
• Paul V Maier,
  Sr. V-P, CFO
• Warner R Broaddus,
  V-P, Gen. Counsel & Secy.
• Elizabeth M Greetham,
  Director
• Henry F Blissenbach,
  Director
• Irving S Johnson,
  Director
• Carl C Peck,
  Director
• Eric S Groves,
  V-P, Project Management
• Giambattista Aliprandi,
  Sr. VP, Tech., Sup & Intl Oper
• James J Litalien,
  Sr. V-P, Reg Affairs & Comp.
• David E Robinson,
  President & CEO
• Tod Mertes,
  V-P, Controller & Treasurer
• Jennifer R. Cochran,
  
• Octavio Espinoza,
  Chief Financial Officer
• Martine Zimmermann,
  Director
• Andrew Reardon,
  CLO & Secretary